Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1619-7089
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma ; day:25 ; month:2 ; year:2021 ; pages:1-2
European journal of nuclear medicine and molecular imaging ; (25.2.2021), 1-2

Urheber
Feuerecker, B.
Mogler, C.
Wörtler, K.
Knebel, C.
Eiber, M.
Krönke, M.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00259-021-05254-x
URN
urn:nbn:de:101:1-2021042222255637722703
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:44 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Feuerecker, B.
  • Mogler, C.
  • Wörtler, K.
  • Knebel, C.
  • Eiber, M.
  • Krönke, M.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors

Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007

PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007

Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT

Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3

Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3

Verbundene Objekte